BLUE BELL, PA
February 25, 2004 - InKine Pharmaceutical Company, Inc.
(Nasdaq: INKP) )today announced the completion of enrollment in the Company's Phase IV study using Visicol® tablets as a laxative in patients with constipation. Visicol® tablets are currently marketed in the United States for cleansing of the bowel prior to colonoscopy in adults. The constipation study is a randomized, open-label, dose ranging, multicenter trial in approximately 40 patients with either chronic functional constipation or constipation-predominant Irritable Bowel Syndrome (IBS). Patients are treated for up to 28 days. The last patient will complete treatment later this quarter, and data from the study are expected to be available shortly thereafter.
“We have already started the process of collecting data from the sites that have completed treating their patients,” said Martin Rose, M.D., J.D., Executive Vice President for Research and Development at InKine. “We look forward to learning more about the dosing and efficacy of Visicol® when used as a laxative in constipated patients. The constipation market represents a potentially large extension of Visicol®'s utility, with over 7.4 million prescriptions filled in 2003 for laxative products,” added Dr. Rose.
About InKine Pharmaceutical
Pharmaceutical Company, Inc. is a publicly traded
biopharmaceutical company focused on the diagnosis and
treatment of cancer and autoimmune diseases. The Company's
development strategy is to acquire late-stage drug
candidates with short time lines to commercialization. The
Company's first product, Visicol™ is the first and only
tablet purgative preparation indicated for bowel cleansing
prior to colonoscopy. InKine's second product, IBStat™, is a
novel oral hysocyamine spray for the treatment of Irritable
Bowel Syndrome (IBS) and spasm of the colon. Additionally,
the Company is developing other clinical compounds such as
Colirest™, which is in clinical trials for the treatment of
Crohn's disease and completed Phase II trials for the
treatment of ulcerative colitis. For further information,
please visit InKine on their web site http://www.inkine.com.
In addition to historical facts or
statement of current condition, this press release may
contain forward-looking statements. Forward-looking
statements provide InKine's current expectations or
forecasts of future events. These may include statements
regarding anticipated scientific progress on its research
programs, development of potential pharmaceutical products,
interpretation of clinical results, prospects for regulatory
approval, manufacturing development and capabilities, market
prospects for its products, sales and earnings projections,
and other statements regarding matters that are not
historical facts. You may identify some of these
forward-looking statements by the use of words in the
statements such as "anticipate," "estimate," "expect,"
"project," "intend," "plan," "believe" or other words and
terms of similar meaning. InKine's performance and financial
results could differ materially from those reflected in
these forward-looking statements due to general financial,
economic, regulatory and political conditions affecting the
biotechnology and pharmaceutical industries as well as more
specific risks and uncertainties such as those set forth in
its reports on Form 10-Q and 10-K filed with the U.S.
Securities and Exchange Commission. Given these risks and
uncertainties, any or all of these forward-looking
statements may prove to be incorrect. Therefore, you should
not rely on any such factors or forward-looking statements.
Furthermore, InKine does not intend (and it is not
obligated) to update publicly any forward-looking
statements. This discussion is permitted by the Private
Securities Litigation Reform Act of